New antiretroviral agents for the treatment of HIV infection

被引：10

作者：

Marks K. ^{[1
]}

Gulick R.M. ^{[1
]}

机构：

[1] Weill Medical College, Cornell University, Cornell Clinical Trials Unit, New York, NY 10021

来源：

Current Infectious Disease Reports | 2004年 / 6卷 / 4期

关键词：

Ritonavir; Tipranavir; 43rd Interscience; Capravirine; Nucleotide Analogue Reverse Transcriptase Inhibitor;

D O I：

10.1007/s11908-004-0056-8

中图分类号：

学科分类号：

摘要：

Issues, such as complexity, tolerability, and drug resistance and cross-resistance, limit the effectiveness of current antiretroviral regimens and make the continued development of newer agents important, despite the availability of 20 approved drugs for the treatment of HIV infection. Many new compounds are in development in existing classes: nucleoside and nucleotide analogue reverse transcriptase inhibitors (eg, D-d4FC and SPD754), non-nucleoside analogue reverse transcriptase inhibitors (eg, capravirine and TMC 125), and protease inhibitors (eg, tipranavir and TMC 114). In addition, newer classes of antiretroviral drugs, such as HIV entry inhibitors (eg, TNX-355, SCH 417690, UK-427,857, AMD 11070), that target the first step in the HIV life cycle are under development. Continued improvement in the treatment of HIV infection will result from the availability of convenient, well-tolerated, and affordable drugs with potent and durable antiretroviral activity. Copyright © 2004 by Current Science Inc.

引用

页码：333 / 339

页数：6

共 46 条

[1]

Geleziunas R., Gallagher K., Zhang H., Et al., HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2′, 3′-dideoxy-2′, 3′-didehydro-5-fluorocytidine (Reverset), Antivir. Chem. Chemother., 14, pp. 49-59, (2003)

[2]

Murphy R.L., Schurmann D., Kravec I., Et al., Pharmacokinetics, safety and antiviral activity of the nucleoside Reverset following single doses in HIV-1 infected patients, (2003)

[3]

Murphy R.L., Schurmann D., Beard A., Et al., Tolerance and potent anti-HIV-1 activity of Reverset following 10 days of mono-therapy in treatment-naïve individuals, (2004)

[4]

Locas C., Ching S., Damment S., Safety profile of SPD754 in Cynomolgus monkeys treated for 52 weeks, (2004)

[5]

Francis R.J., Lanclos L., Shiveley L., Sawyer J., Pharmacokinetics of SPD754, a new cytidine analogue in healthy volunteers, (2003)

[6]

Cahn P., Lange J., Cassetti I., Et al., Anti-HIV-1 activity of SPD754, a new NRTI: Results of a 10 day monotherapy study in treatment-naive HIV patients, (2003)

[7]

Collins P., Shiveley L., Anderson C., Bethell R., Analysis of the genotypes of viruses isolated from patients after 10 days monotherapy with SPD754, (2004)

[8]

Bethell R., Adams J., De Muys J., Et al., Pharmacological evaluation of a dual deoxycytidine analogue combination: 3TC and SPD754, (2004)

[9]

Fujiwara T., Sato A., El-Farrash M., Et al., S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1, Antimicrob. Agents Chemother., 42, pp. 1340-1345, (1998)

[10]

Hayashi S., Amantea M., Hawley P., Et al., Effects of fasting (F), high fat (H) and low fat (L) meals on the pharmacokinetics (PK) of a single oral dose of capravirine (CPV), a nonnucleoside reverse transcriptase inhibitor (NNRTI), in healthy volunteers, (2000)

← 1 2 3 4 5 →